Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 2/20 | 0.39 |
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4335029 | 0.74 | GLS (0.47) | KHKHRH3GLS | |
| SCHEMBL5950192 | 0.73 | HRH3 (0.43) | POLBKMT2AHRH3ALDH1A1KDM4E | |
| SCHEMBL21135573 | 0.72 | CDK8 (0.46) | POLBHTTKMT2AKHKMAP4K4 | |
| SCHEMBL28378104 | 0.70 | GLS (0.40) | POLBKMT2AKHKHRH3GLS | |
| SCHEMBL28712904 | 0.69 | HRH3 (0.38) | KMT2AHRH3GLSALDH1A1KDM4E | |
| SCHEMBL30455873 | 0.68 | HRH3 (0.34) | KMT2AHRH3GLSALDH1A1KDM4E | |
| SCHEMBL1026858 | 0.68 | HRH3 (0.47) | HRH3GLS | |
| SCHEMBL21135447 | 0.67 | CYP2D6 (0.52) | POLBHTTKMT2AMAP4K4TYMP | |
| SCHEMBL21135739 | 0.67 | CYP2D6 (0.52) | POLBHTTKMT2AMAP4K4TYMP | |
| SCHEMBL30089630 | 0.67 | HRH3 (0.40) | KMT2AHRH3GLSADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3371196-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PLATELET AGGREGATION | UNIV MONTREAL (CA) | 2021-10-27 | — | — | EP | disclosed |
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | UNIVERSITE DE MONTREAL (CA) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329307-B2 | Heterocyclic compounds as inhibitors of platelet aggregation | F12, F2, F3 | POLB 4358/4885HTT 2643/4885KMT2A 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.